Evidence map›Paper›PMID 35213624›Full record

ArticlePloS one2022

Multiple subregions within the caveolin-1 scaffolding domain inhibit fibrosis, microvascular leakage, and monocyte migration.

Charles F Reese, Panneerselvam Chinnakkannu, Elena Tourkina, Stanley Hoffman, Dhandapani Kuppuswamy

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. p53-miR-34a feedback in lung fibroblasts regulates antifibrotic effects of CSP7, nintedanib, and pirfenidone.American journal of physiology. Lung cellular and molecular physiology · 2025
    Article
  2. Review
  3. Revolutionizing Autoimmune Research: The Role of Caveolin-1.Immunity, inflammation and disease · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Role of Caveolin-1 in Sepsis - A Mini-Review.Frontiers in immunology · 2022
    Review
  11. Involvement of caveolin-1 in skin diseases.Frontiers in immunology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Charles F ReeseDivision of Rheumatology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, Unites States of America.ORCID 0000-0001-9715-4484
Panneerselvam ChinnakkannuDivision of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, Unites States of America.
Elena TourkinaDivision of Rheumatology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, Unites States of America.
Stanley HoffmanDivision of Rheumatology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, Unites States of America.
Dhandapani KuppuswamyDivision of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, Unites States of America.ORCID 0000-0002-7948-038X
Medical University of South Carolina · US

Funding

TRAINING TO IMPROVE CARDIOVASCULAR THERAPIEST32HL007260 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MENICK, DONALD R. · 1985 to 2021
$11.1M
South Carolina Clinical & Translational Research Institute (SCTR)TL1TR001451 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI FEGHALI-BOSTWICK, CAROL A. · 2015 to 2024
$4.6M
Pulmonary Focused Foundations in Innovation and Scholarship (PuFFInS)T32HL144470 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Carol A. Feghali-Bostwick · 2019 to 2026
$2.6M
NCATS NIH HHS TL1 TR001451NHLBI NIH HHS T32 HL007260NHLBI NIH HHS T32 HL144470
6 · The paper itself

Abstract

The caveolin-1 scaffolding domain (CSD, amino acids 82-101 of caveolin-1) has been shown to suppress bleomycin-induced lung and skin fibrosis and angiotensin II (AngII)-induced myocardial fibrosis. To identify active subregions within CSD, we split its sequence into three slightly overlapping 8-amino acid subregions (82-89, 88-95, and 94-101). Interestingly, all three peptides showed activity. In bleomycin-treated mice, all three subregions suppressed the pathological effects on lung and skin tissue morphology. In addition, while bone marrow monocytes isolated from bleomycin-treated mice showed greatly enhanced migration in vitro toward CXCL12, treatment in vivo with CSD and its subregions almost completely suppressed this enhanced migration. In AngII-induced heart failure, both 82-89 and 88-95 significantly suppressed fibrosis (both Col I and HSP47 levels), microvascular leakage, and heart weight/ body weight ratio (HW/BW) while improving ventricular function. In contrast, while 94-101 suppressed the increase in Col I, it did not improve the other parameters. The idea that all three subregions can be active depending on the assay was further supported by experiments studying the in vitro migration of human monocytes in which all three subregions were extremely active. These studies are very novel in that it has been suggested that there is only one active region within CSD that is centered on amino acids 90-92. In contrast, we demonstrate here the presence of other active regions within CSD.

Indexed as

Cell MovementAnimalsBleomycinCaveolin 1MiceMonocytesPulmonary FibrosisSkin DiseasesBleomycinCav1 protein, mouseCaveolin 1

Identifiers

PMID35213624
PMCPMC8880820
OpenAlexW4214724947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.